The stock of Exact Sciences Corp. (NASDAQ:EXAS) last traded at $72.82, down -1.25% from the previous session.
EXAS stock price is now 17.17% away from the 50-day moving average and 0.39% away from the 200-day moving average. The market capitalization of the company currently stands at $13.22B.
With the price target maintained at $91, The Benchmark Company recently Upgraded its rating from Hold to Buy for Exact Sciences Corp. (NASDAQ: EXAS). On December 14, 2023, Guggenheim recently initiated its ‘Buy’ rating on the stock quoting a target price of $90, while ‘Wolfe Research’ rates the stock as ‘Outperform’
In other news, Baranick Brian, EVP, GM., Precision Oncology sold 924 shares of the company’s stock on Apr 02 ’24. The stock was sold for $73,393 at an average price of $79.43. Upon completion of the transaction, the EVP, GM., Precision Oncology now directly owns 13,171 shares in the company, valued at $0.96 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 01 ’24, EVP, Human Resources Condella Sarah sold 2,000 shares of the business’s stock. A total of $140,000 was realized by selling the stock at an average price of $70.00. This leaves the insider owning 71,787 shares of the company worth $5.23 million. A total of 1.04% of the company’s stock is owned by insiders.
During the past 12 months, Exact Sciences Corp. has had a low of $56.05 and a high of $100.77. As of last week, the company has a debt-to-equity ratio of 0.82, a current ratio of 2.32, and a quick ratio of 2.07. The fifty day moving average price for EXAS is $62.29 and a two-hundred day moving average price translates $71.63 for the stock.
The latest earnings results from Exact Sciences Corp. (NASDAQ: EXAS) was released for Dec, 2023. According to the Diagnostics & Research Company, earnings per share came in at -$0.27, beating analysts’ expectations of -$0.46 by 0.19. This compares to -$0.72 EPS in the same period last year. The net profit margin was -8.17% and return on equity was -6.60% for EXAS. The company reported revenue of $646.88 million for the quarter, compared to $553.0 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 16.98 percent. For the current quarter, analysts expect EXAS to generate $628.92M in revenue.
Exact Sciences Corp.(EXAS) Company Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test’s performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
